Adam Widman, MD The Widman Lab within the Digital Oncology Program at MSKCC is using machine learning and genomics to engineer the next-generation of ultrasensitive, highly scalable liquid biopsies for early cancer detection, treatment monitoring, and detection of minimal residual disease (MRD) after surgery for early-stage cancer.